Following is a cumulative list of Hoosier Cancer Research Network publications in prostate cancer.

Manuscripts and Journal Articles

• Hahn NM, Yiannoutsos, CT, Kirkpatrick K, Sharma J, Sweeney, CJ. Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event: Hoosier Oncology Group GU02-41 Clin Genitourin Cancer 2014Fe;12(1):33-40.e4 doi: 10.1016/j.clgc.2013.07.002. Epub 2013 Oct 12.
• NM Hahn, RT Zon, M Yu, FO Ademuyiwa, T Jones, W Dugan, C Whalen, R Shanmugam, T Skaar, CJ Sweeney. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology 20: 1971–1976, 2009; doi:10.1093/annonc/mdp244; Published online 15 July 2009. See abstract.
• Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis: GU00-9 Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6094-9. PMID: 17062685
• Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. A Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis: A Hoosier Oncology Group Study GU00-9. Clin Cancer Res 2006;12(20) October 15, 2006.
• Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group Study GU98-2. J Clin Oncol. 2005 Feb 20;23(6):1185-91 PMID: 15718315
• Sweeney CJ, Monaco F, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM,
  Einhorn LH. A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone Refractory Prostate Cancer: GU98-1. Annals of Oncology 13: 435-440, 2002
• Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial: GU98-3. J Clin Oncol. 1999 Oct;17(10):3160-6 PMID: 10506613
• Hudes G, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L, Roth B. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients with Hormone Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial GU93-1. J Clin Oncology Vol 17, No 10 (October), 1999:pp 3160-3166
• Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J, Einhorn L: Phase III Trial of Cyclophosphamide Versus Cyclophosphamide, Doxorubicin and Methotrexate in Hormone-Refractory Prostatic Cancer: A Hoosier Oncology Group Study. Cancer 70:2488-2492, 1992.

Abstracts, Posters, and Presentations

• RR McKay, L Liu, M Pu, A Araneta, L Wang, N Castano, J Gomez, A Ajmera, H Ye, R Pili, K Runcie, D Joseph McHugh, K Offit, C Judith Paller, NB Haas, J Javier-Desloges, CJ Kane, TM Seibert, A Bagrodia. A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune) (HCRN-GU20-436). Poster Presentation, 2024 ASCO. See abstract. 
• Y Chen, L Liu, M Pu, S Pena, Q Qin, T Zhang, H Emamekhoo, J Michael Lang, A Patnaik, RR McKay. A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY) (HCRN-GU21-517). Trials in Progress, 2024 ASCO GU. See abstract. 
• RR McKay, L Liu, M Pu, A Araneta, L Wang, N Castano, J Gomez, A Ajmera, H Ye, R Pili, K Runcie, D Joseph McHugh, K Offit, C Judith Paller, NB Haas, J Javier-Desloges, CJ Kane, TM Seibert, A Bagrodia. A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune) (HCRN-GU20-436). Trials in Progress, 2024 ASCO GU. See abstract. 
• Kim N. Chi, Mark T. Fleming, Katherine Sunderland, Costantine Albany, Joel Gingerich, Fred Saad, Scott A. North, Alexander Starodub, Richard C. Lauer, Joseph D. Ruether, Madelaine Miranda Sgroi, Mark C. Scholz, Christopher Sweeney. PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI) (HCRN GU12-159). Accepted to Poster Session A at the ASCO 2017 Genitourinary Cancers Symposium, February 16-18, 2017, Orlando, Fla. J Clin Oncol 35, 2017 (suppl 6S; abstract 146). See abstract.
• John Paul Flores, Paul Mathew. Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU14-202. Accepted as a trials in progress poster at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr TPS5095). See abstract.
• Choueiri TK, Hahn NM, Alva AS, Lauer RC, Dreicer R, Picus J, Pili R, Balar AV, Sonpavde G, Hoffman-Censits JH, Guancial EA, Alter R, Regan MM, Jacobs C, Stewart PS, Pal SK, Rosenberg JE. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. Hoosier Oncology Group GU12-160. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 29 – June 2, 2015, Chicago IL.J Clin Oncol 33:5s, 2015 (suppl; abstr TPS4577)
• T.K. Choueiri, N.M. Hahn, S.K. Pal, A.S. Alva, R. Dreicer, A. Starodub, G. Sonpavde, J. H. Hoffman-Censits, J. Picus, A.V. Balar, E.A. Guancial, M.M. Regan, C. Jacobs, P.S. Stewart, J.E.. Rosenberg. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. Hoosier Oncology Group GU12-160. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4593^).
• J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney. Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer: Hoosier Oncology Group GU02-41. Accepted to the general poster session at the ASCO Annual Meeting June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 4594)
• C. Sweeney, W. M. Dugan II, R. Dreicer, F. Chu, G. Parks, K. Baker, D. Reed, K. Jansz, J. Zadra, C. T. Yiannoutsos. A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC): Hoosier Oncology Group GU02-41. Accepted to the ASCO Annual Meeting, June 4-8, 2010, Chicago, IL. J Clin Oncol 28, 2010 (suppl; abstr e15000)
• N.M. Hahn, F. Ademuyiwa, R.T. Zon, T. Jones, W. Dugan, C. Whalen, M. Yu, R. Shanmugam, T. Skaar, C.J. Sweeney. A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis: GU03-67. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
• N. M. Hahn, C. Whalen, C. J. Sweeney. Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group GU03-67. Preliminary analysis. Presented at the general poster session at the ASCO Annual Meeting, June 2-6, 2006, Atlanta, Georgia J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4644.
• Christopher Sweeney, Lacey Dobrolecki, Tomasz Beer, Linda Battiato, Jake Vinson, Robert Hickey. Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease. ASCO Multidisciplinary Prostate Cancer Symposium 2005.
• N. M. Hahn, W. Fisher, R. Langdon, R. Zon, M. Browning, C. Calley, C. J. Sweeney. A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC): Hoosier Oncology Group GU00-09. Presented as part of the Scientific Program in the Genitourinary (Prostate) Cancer Poster Discussion, at the ASCO Annual Meeting, May 13 – 17, 2005, Orlando, FL. J Clin Oncology, Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4568
• G. Hudes, E. Ross, B. Roth, A.Balsham, P. Loehrer, H. Ramsey, J. Sprandio, M. Entmacher, W. Dugan, R. Ansari, L. Einhorn. Fox Chase Cancer Center, Philadelphia, PA and Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, IN. Improved Survival for Patients with Hormone-Refractory Prostate Cancer Receiving Estramustine-Based Antimicrotubule Therapy: Final Report of a Hoosier Oncology Group and Fox Chase Network Phase III Trial Comparing Vinblastine and Vinblastine Plus Oral Estramustine Phosphate GU93-1. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL
• Sweeney C, Monaco F, Hanna N, Wasielewski M, Picus J, Ansari A, Dugan W, Einhorn LH. Phase II Study of Weekly Vinorelbine and Estramustine for Hormone Refractory Prostate Cancer (HRPC): a Hoosier Oncology Group and Walther Cancer Institute trial GU98-1 Accepted to the ASCO annual meeting May 20-23, 2000, New Orleans, LA
• Hudes G, Roth B, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L. A Phase III Trial of Vinblastine Versus Vinblastine plus Estramustine Phosphate for Metastatic Hormone-refractory Prostate Cancer (HRPC). A Hoosier Oncology Group, Walther Cancer Institute Fox Chase Network trial: GU93-1. Accepted to the ASCO annual meeting May 17-20, 1997, Denver, CO.
• Drasga R, Ansari R, Rynard S, Wheeler B, McClean J, Einhorn L: A Prospective Randomized Trial of Cyclophosphamide Versus Cyclophosphamide plus Adriamycin plus Methotrexate in Hormone Refractory Prostate Cancer: A Hoosier Oncology Group Study. Slide presentation at ASCO, Washington D.C., May l990. Proc Am Soc Clin Oncol 9:142, 1990.